Why the study?
AF is common in CF-LVAD patients, with many developing new-onset AF post-implantation, prompting a review of its effects on LVAD physiology and outcomes.
What is the impact of atrial fibrillation on pathophysiology and outcomes in patients with continuous flow-left ventricular assist devices?
What is the impact of atrial fibrillation on pathophysiology and outcomes in patients with continuous flow-left ventricular assist devices?
This review highlights the significant pathophysiological impact of atrial fibrillation in CF-LVAD patients, including increased risks of pump thrombosis, stroke, and right ventricular failure.
Answers are grounded in this paper and cite their sources.
AF warrants consideration in CF-LVAD risk assessment; leaves open prospective trials of rhythm strategies on thrombosis and RV failure.
Continuous Flow -Left Ventricular Assist Devices (CF-LVADs) remain the mainstay in end stage HFrEF patients with refractory Stage D HF. AF is common in patients supported on CF-LVADs, with a significantly increasing number developing new-onset AF post LVAD implantation. This review will summarize the effects of atrial fibrillation on LVAD physiology and its impact on outcomes. Literature search for this qualitative review was done using Google Scholar and PubMed. Only studies in adult human LVAD patients were included. The keywords used were atrial fibrillation in LVADs, effect of atrial fibrillation on functional mitral regurgitation /tricuspid regurgitation, effect on right ventricular failure, pump thrombosis and stroke and gender differences in outcomes.The main aspects addressed are effect on LVAD hemodynamics, the complexinteractions between low pulse pressure and atrial fibrillation leading to pump thrombosis and stroke , the role of atrial fibrillation in the initiation and progression ofright ventricular failure, impact on valvular regurgitation (Functional Mitral /TricuspidRegurgitation), utility of Cardiac Resynchronization Therapy post LVAD implant anduse of AI-driven technologies in risk factor identification to help identify novel risk factors important in predicting prognosis to improve outcomes. Use of AI technologies to identify novel risk factors for atrial fibrillation post LVADsurgery is warranted in the context of race, ethnicity and gender. Further studies areneeded to address optimal pacing strategies in LVAD patients with cardiac resynchronization therapy to institute guidelines for use of this therapy post LVAD implantation especially in the context of co-existing atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: